【前期回顾】：Immundiagnostik常见单抗类药物与抗药物抗体(ADA)检测工具汇总

英夫利昔单抗(Infliximab)与抗Infliximab抗体: 

英夫利昔单抗(Infliximab)有的是类抑制性TNFα的药剂，其主要用在克罗恩病, 类类风湿软骨炎, 强直性脊椎骨炎，头层牛皮癣软骨炎，胃溃疡性乙状结肠炎的减轻症状和的控制。抗TNFα的控制的临床检验改善作用一般与的控制性抗原的谷盐氧化还原电位相应的，即下做次APP抗TNFα抗原开始之前的药剂盐氧化还原电位。有几各种因素不良表现谷盐氧化还原电位，在当中属于抗TNFα拮抗剂输注的标准容量和频段、疫情促销活动度、每一个人药代冲力学结构和免疫力不良表现（演变成抗药剂抗原，ADA）。人类相信，ADA在工作性上结合了的控制性抗原或诱导性其加快消失。ADA演变成的不良影响能够是的控制无效和抗TNFα抗原APP当天的过敏性鼻炎不良表现。  

检测的意义：检测抗英夫利昔单抗(Infliximab)药物水平可帮助监测药物水平（尤其是谷浓度），以确保药物在循环中有足够的浓度，并在必要时调整其剂量。此外，在治疗过程中，谷浓度降低表明存在药物抗体。   如果患者体内产生抗英夫利昔单抗(Infliximab)抗体，则𒆙使用抗体药的疗法会导致无用的免疫反应。这可能导致过敏反应，导致疗效降低以及治疗失败。对抗英夫利昔单抗(Infliximab)抗体水平的监测有利于早期干预（例如，增加药物剂量或频率，增加给药免疫抑制药物，切换另一种药物），从而实现有效治疗，降低副作用。   

在这里欧宝体育官方 为大家提供知名的诊断试剂和服务供应商Immundiagnostik（IDK）公司研发的爆款欧宝体育官方 ——抗英夫利昔单抗(Infliximab)药物水平检测试剂盒和抗英夫利昔单抗(Infliximab)ADA水平检测试剂盒：

相关欧宝体育官方 推荐：

欧宝体育官方 名称：	英夫利昔(Infliximab)单抗药物浓度检测试剂盒	总抗英夫利昔(Infliximab)单抗抗体检测试剂盒	游离抗英夫利昔(Infliximab)单抗抗体检测试剂盒
货号：	K 9655	K 9654	K 9650
规格：	96T	96T	96T
孵育时间：	1h/1h/10-20min	20min/1h/1.5h/10-20min	过夜/1h/10-20min
样本类型	血清、EDTA血浆	血清、EDTA血浆	血清、EDTA血浆
上样量	10?l	25?l	50?l
灵敏度	LoB(空白限)= 1.998ng/ml	LoB(空白限)= 3.12 AU/ml	LoB(空白限)= 5.751 AU/ml
校准品	4.15-225ng/ml

*以下欧宝体育官方 仅应用在科研管理，严禁做医疗管理及物理诊断贷款用途  

储存条件及有效期：本欧宝体育官方 在2-8℃下保存可稳定至所标示的有效期。 工作任务洗液自制后须存贮于封好容器类中，在2-8℃下可保留图片9个月。 组合物稀释溶液后不安稳，是没办法保留图片，须现配所用。 产出年份英文及损坏年份英文见免疫试剂盒标贴。  

适用仪器：支持于极具450nm、620nm激发光谱的所有全半自主、半半自主酶标仪。  

样本类型：EDTA血浆和血清

样本保存：新鲜的采摘的EDTA血浆或血清在常温（15-30℃）或2-8℃下可另存7天，若须太久另存，请放置于-20℃下另存。 已稀释溶液的EDTA血浆或血清模本在常温下可另存7天，在2-8℃可另存三十天，在-20℃不少可另存7周。应要量防范多次冻融，冻融两次不已经💎超过3次  

K 9655部分引文：

1. Afif W, Loftus E V, Faubion WA, Kane S V, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. The American journal of gastroenterology. 2010/02/11. 2010 May;105(5):1133–9.
2. Beglinger C, Binek J, Braegger C, Michetti P, Rogler G, Sauter B, et al. InfliximabMonotherapie versus Kombinationstherapie mit Immunmodulatoren. The medical journal. 2008;1:32–4.
3. Bender NK, Heilig CE, Dr?ll B, Wohlgemuth J, Armbruster F-P, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatology international. 2006/09/29. 2007 Jan 11;27(3):269–74.
4. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis and rheumatism. 2006 Dec;54(12):3782–9.
5. Bradley JR. TNF-mediated inflammatory disease. The Journal of pathology. 2008 Jan;214(2):149–60.
6. St Clair EW, Wagner CL, Fasanmade A a, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis and rheumatism. 2002 Jun;46(6):1451–9.
7. Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nature clinical practice Gastroenterology & hepatology. 2006 Apr;3(4):220–8.
8. Colombel J-F, Loftus E V, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan;126(1):19–31.
9. Cominelli F. Cytokine-based therapies for Crohn’s disease--new paradigms. The New England journal of medicine. 2004 Nov 11;351(20):2045–8.
10. Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, C

K 9654部分引文：

1. Afif W, Loftus EV, Jr., Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ (2010). Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105(5): 1133-1139.
2. Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S (2012). Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 18(9): 1628-1633.
3. Tak PP (2012). A personalized medicine approach to biological treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 51(4): 600-609.
4. Ordas I, Mould DR, Feagan BG, Sandborn WJ (2012) Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91(4): 635-646.
5. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B (2007). Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27(3): 269-274.

K 9650部分引文：

1. Afif, W. et al., 2010. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. The American journal of gastroenterology, 105(5), pp.1133–9.
2. Kopylov, U. et al., 2012. Clinical utility of antihuman lambda chain-based enzymelinked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflammatory bowel diseases, 18(9), pp.1628–33.
3. Tak, P.P., 2012. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford, England), 51(4), pp.600–9.
4. Ordás, I. et al., 2012. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clinical pharmacology and therapeutics, 91(4), pp.635–46.
5. Bender, N.K. et al., 2007. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatology international, 27(3), pp.269–74.

了解到这里，您喜爱多会儿？赶紧练习小艾吧！